74 related articles for article (PubMed ID: 20951313)
21. Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review.
Nair AS; Jayan AP; Anandu KR; Saiprabha VN; Pappachen LK
Mol Cell Biochem; 2023 Dec; 478(12):2875-2890. PubMed ID: 37014561
[TBL] [Abstract][Full Text] [Related]
22. [Molecular mechanisms of atherogenesis associated with aging].
Komuro I; Minamino T
Nihon Ronen Igakkai Zasshi; 2007 Jan; 44(1):23-6. PubMed ID: 17337842
[No Abstract] [Full Text] [Related]
23. Key signaling pathways and targets in lung cancer therapy.
Choong NW; Salgia R; Vokes EE
Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S52-60. PubMed ID: 17382025
[TBL] [Abstract][Full Text] [Related]
24. Shining a light on metabolic vulnerabilities in non-small cell lung cancer.
Dowling CM; Zhang H; Chonghaile TN; Wong KK
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188462. PubMed ID: 33130228
[TBL] [Abstract][Full Text] [Related]
25. Sprouty 2 gene in mouse lung tumorigenesis.
Minowada G; Miller YE
Chest; 2004 May; 125(5 Suppl):111S. PubMed ID: 15136453
[No Abstract] [Full Text] [Related]
26. Lung Cancer: Are we up to the Challenge?
Esposito L; Conti D; Ailavajhala R; Khalil N; Giordano A
Curr Genomics; 2010 Nov; 11(7):513-8. PubMed ID: 21532835
[TBL] [Abstract][Full Text] [Related]
27. Mutation may lead to new lung treatment.
Nurs Stand; 1990 Apr; 4(28):14. PubMed ID: 27238325
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Methylation Panel in the Promoter Region of
Mohammed F; Baydaa Abed Hussein A; Ahmed T
Arch Razi Inst; 2022 Jun; 77(3):1075-1081. PubMed ID: 36618318
[TBL] [Abstract][Full Text] [Related]
29. Ginsenoside Rk1 inhibits cell proliferation and promotes apoptosis in lung squamous cell carcinoma by calcium signaling pathway.
An X; Fu R; Ma P; Ma X; Fan D
RSC Adv; 2019 Aug; 9(43):25107-25118. PubMed ID: 35528653
[TBL] [Abstract][Full Text] [Related]
30. Genistein inhibits lung cancer cell stem-like characteristics by modulating MnSOD and FoxM1 expression.
Fu Z; Cao X; Liu L; Cao X; Cui Y; Li X; Quan M; Ren K; Chen A; Xu C; Qiu Y; Chen X; Wang Z; Cao J
Oncol Lett; 2020 Sep; 20(3):2506-2515. PubMed ID: 32782570
[TBL] [Abstract][Full Text] [Related]
31. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer.
Shang JL; Ning SB; Chen YY; Chen TX; Zhang J
Acta Pharmacol Sin; 2021 Jan; 42(1):120-131. PubMed ID: 32541922
[TBL] [Abstract][Full Text] [Related]
32. SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC.
Yuan M; Xu LF; Zhang J; Kong SY; Wu M; Lao YZ; Zhou H; Zhang L; Xu H
Front Oncol; 2019; 9():586. PubMed ID: 31428570
[TBL] [Abstract][Full Text] [Related]
33. New insights into spectral histopathology: infrared-based scoring of tumour aggressiveness of squamous cell lung carcinomas.
Gaydou V; Polette M; Gobinet C; Kileztky C; Angiboust JF; Birembaut P; Vuiblet V; Piot O
Chem Sci; 2019 Apr; 10(15):4246-4258. PubMed ID: 31057753
[TBL] [Abstract][Full Text] [Related]
34. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
35. TASK-1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial-mesenchymal transition in lung cancer.
Wang XG; Yuan NX; Li XP; Chen FF
Exp Ther Med; 2018 Jan; 15(1):365-370. PubMed ID: 29387193
[TBL] [Abstract][Full Text] [Related]
36. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
[TBL] [Abstract][Full Text] [Related]
37. Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.
Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
Oncotarget; 2017 Mar; 8(11):18166-18176. PubMed ID: 28199989
[TBL] [Abstract][Full Text] [Related]
38.
Aztopal N; Cevatemre B; Sarimahmut M; Ari F; Dere E; Ozel MZ; Firat M; Ulukaya E
Oncol Lett; 2016 Aug; 12(2):1429-1437. PubMed ID: 27446448
[No Abstract] [Full Text] [Related]
39. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
